10.6084/m9.figshare.6803771.v1 de la Rosa Carrillo D. de la Rosa Carrillo D. Navarro Rolon A. Navarro Rolon A. Girón Moreno R.M. Girón Moreno R.M. Montull Veiga B. Montull Veiga B. Olveira Fuster C. Olveira Fuster C. Padilla Galo A. Padilla Galo A. Prados Sánchez C. Prados Sánchez C. Quintana Gallego E. Quintana Gallego E. Sibila Vidal O. Sibila Vidal O. Celorrio Jiménez N. Celorrio Jiménez N. Ruiz Peña A. Ruiz Peña A. Torres Martí A. Torres Martí A. Avilés Inglés M.J. Avilés Inglés M.J. Blanco Aparicio M. Blanco Aparicio M. García-Clemente M. García-Clemente M. Golpe Gómez R. Golpe Gómez R. Gómez Bonilla A. Gómez Bonilla A. Gómez González C. Gómez González C. Leal Arranz M.V. Leal Arranz M.V. Mínguez Clemente P. Mínguez Clemente P. López Muñiz B. López Muñiz B. Máiz Carro L. Máiz Carro L. Pando Sandoval A. Pando Sandoval A. Rodríguez Hermosa J.L. Rodríguez Hermosa J.L. Uranga Echeverria A. Uranga Echeverria A. Núñez Ares A. Núñez Ares A. López Roldán L. López Roldán L. Abellán Martínez C. Abellán Martínez C. Martínez García A.J. Martínez García A.J. Michel de la Rosa F.J. Michel de la Rosa F.J. Godoy Mayoral R. Godoy Mayoral R. Martínez-García M.Á. Martínez-García M.Á. Supplementary Material for: Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis Karger Publishers 2018 Antibiotic treatment Bronchiectasis Costs Hospitalization Pseudomonas aeruginosa colonization 2018-07-11 11:10:21 Dataset https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Cost_of_Hospitalizations_due_to_Exacerbation_in_Patients_with_Non-Cystic_Fibrosis_Bronchiectasis/6803771 <b><i>Background:</i></b> Knowing the cost of hospitalizations for exacerbation in bronchiectasis patients is essential to perform cost-effectiveness studies of treatments that aim to reduce exacerbations in these patients. <b><i>Objectives:</i></b> To find out the mean cost of hospitalizations due to exacerbations in bronchiectasis patients, and to identify factors associated with higher costs. <b><i>Methods:</i></b> Prospective, observational, multicenter study in adult bronchiectasis patients hospitalized due to exacerbation. All expenses from the patients’ arrival at hospital to their discharge were calculated: diagnostic tests, treatments, transferals, home hospitalization, admission to convalescence centers, and hospitals’ structural costs for each patient (each hospital’s tariff for emergencies and 70% of the price of a bed for each day in a hospital ward). <b><i>Results:</i></b> A total of 222 patients (52.7% men, mean age 71.8 years) admitted to 29 hospitals were included. Adding together all the expenses, the mean cost of the hospitalization was EUR 5,284.7, most of which correspond to the hospital ward (86.9%), and particularly to the hospitals’ structural costs. The adjusted multivariate analysis showed that chronic bronchial infection by <i>Pseudomonas aeruginosa</i>, days spent in the hospital, and completing the treatment with home hospitalization were factors independently associated with a higher overall cost of the hospitalization. <b><i>Conclusions:</i></b> The mean cost of a hospitalization due to bronchiectasis exacerbation obtained from the individual data of each episode is higher than the cost per process calculated by the health authorities. The most determining factor of a higher cost is chronic bronchial infection due to <i>P. aeruginosa</i>, which leads to a longer hospital stay and the use of home hospitalization.